Roopal Thakkar is now leading AbbVie's CSO team, bringing a wealth of experience to the role.
With a strong background in pharmaceutical research and development, Thakkar is poised to drive innovation and growth at AbbVie.
AbbVie Appoints Roopal Thakkar as CSO
Roopal Thakkar has been appointed as the Chief Scientific Officer (CSO) at AbbVie. He will lead the company's global R&D organization of more than 14,000 team members across all phases of discovery and development.
Dr. Thakkar has a deep commitment to innovation and patient care, which is reflected in his previous roles at AbbVie, including Vice President, Global Regulatory Affairs and R&D Quality Assurance. He has also held positions in clinical development, including Group Project Director, Immunology.
In his new role, Dr. Thakkar will be responsible for the six major R&D centers of excellence located across the United States, Germany, and Japan. He will also focus on driving pipeline advancement across therapeutics and aesthetics.
Dr. Thakkar's experience and skills make him an excellent fit for the role, as he has a proven track record in building new capabilities, forging strategic partnerships, and advancing clinical programs. He has also been instrumental in shaping AbbVie's approach to early-stage science and developing data strategies to accelerate drug discovery and development.
Here are some key facts about Dr. Thakkar's new role:
- He will lead a global R&D organization of over 14,000 team members.
- He will be responsible for six major R&D centers of excellence.
- He will focus on driving pipeline advancement across therapeutics and aesthetics.
- He will continue to build momentum across discovery and all stages of development.
Dr. Thakkar is excited to assume these new responsibilities and is looking forward to leading the R&D organization at AbbVie. He is committed to ensuring AbbVie's growth well into the next decade and is dedicated to addressing the most challenging health issues for patients.
New CSO's Background
Dr Thakkar joined Abbott/AbbVie in 2003 and has progressed through several positions in clinical development.
He trained in internal medicine and was clinical fellow at the University of Alabama, Birmingham, and at Wake Forest University School of Medicine.
Dr Thakkar obtained his bachelor’s degree in cellular and molecular biology from the University of Michigan.
He also holds an MD from the Wayne State University School of Medicine, US.
Dr Thakkar has held various leadership roles within the company, including group project director, immunology, and vice president and global regulatory affairs.
In 2019, Dr Thakkar took on the role of vice president, global regulatory affairs and R&D quality assurance, and in 2022 he was appointed as senior vice president, development and regulatory affairs and chief medical officer.
As Executive Vice President, Research & Development and Chief Scientific Officer, AbbVie, Dr Thakkar is also responsible for the six major R&D centres of excellence located across the US, Germany, and Japan.
AbbVie's R&D Leadership
Roopal Thakkar, M.D. leads AbbVie's global R&D organization of more than 14,000 team members.
Dr. Thakkar is responsible for six major R&D centers of excellence located across the United States, Germany, and Japan.
He has a deep commitment to innovation and patient care, and an excellent track record in building new capabilities, forging strategic partnerships, and advancing clinical programs.
Dr. Thakkar's experience includes leading the organization through strategic acquisitions and propelling clinical development programs across various therapeutic areas.
Prior to joining AbbVie, he completed training in internal medicine and was a clinical fellow at the University of Alabama, Birmingham, and at Wake Forest University School of Medicine.
Thomas J. Hudson, M.D. previously held the position of senior vice president, Chief Scientific Officer, global research, and will be retiring from AbbVie.
Dr. Hudson joined AbbVie in 2016 and oversaw oncology discovery and early development before assuming the role of vice president, discovery research.
He was appointed to the role of Chief Scientific Officer in 2019.
Dr. Thakkar assumed the role of vice president, global regulatory affairs and R&D quality assurance in 2019, and was later appointed to the role of senior vice president, development and regulatory affairs and Chief Medical Officer in 2022.
Additional reading: Tom Hudson Abbvie
Featured Images: pexels.com
